{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:44Z","timestamp":1792783664581,"version":"4.5.0"},"reference-count":202,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"am","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"CCITLA"},{"DOI":"10.13039\/100000002","name":"National Cancer Institute of the National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.beha.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T08:55:04Z","timestamp":1549788904000},"page":"74-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Myeloid disorders after autoimmune disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Prajwal C.","family":"Boddu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2019.02.002_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.blre.2016.11.002","article-title":"Therapy-related myelodysplastic syndromes, or are they?","volume":"31","author":"Abou Zahr","year":"2017","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib4","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Canc J Clin"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib5","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Canc J Clin"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-016-2862-0","article-title":"The importance of erythroblast enumeration in myeloid neoplasia","volume":"96","author":"Zeidan","year":"2017","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2017.33","article-title":"Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS clinical research consortium","volume":"31","author":"Zeidan","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Canc"},{"issue":"14","key":"10.1016\/j.beha.2019.02.002_bib10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/bloodadvances.2017007369","article-title":"Therapy-related myelofibrosis does not appear to exist","volume":"1","author":"Masarova","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1309\/NQ3PMV4U8YV39JWJ","article-title":"Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant","volume":"127","author":"Singh","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/gcc.10042","article-title":"21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop","volume":"33","author":"Slovak","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"issue":"22","key":"10.1016\/j.beha.2019.02.002_bib14","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1182\/blood.V128.22.5930.5930","article-title":"Systematic literature review of the global incidence and prevalence of myelodysplastic syndrome and acute myeloid leukemia","volume":"128","author":"Lubeck","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.002_bib15","article-title":"Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it","author":"Zeidan","year":"2018","journal-title":"Blood Rev"},{"issue":"46","key":"10.1016\/j.beha.2019.02.002_bib16","doi-asserted-by":"crossref","first-page":"80103","DOI":"10.18632\/oncotarget.21178","article-title":"Risk stratification in therapy-related myelodysplastic syndromes","volume":"8","author":"Zeidan","year":"2017","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.beha.2019.02.002_bib17","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(16)30147-4","article-title":"Monogenic and polygenic determinants of sarcoma risk: an international genetic study","volume":"17","author":"Ballinger","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","article-title":"Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience","volume":"33","author":"Wolff","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib21","doi-asserted-by":"crossref","first-page":"e0184747","DOI":"10.1371\/journal.pone.0184747","article-title":"Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: a population-based study","volume":"12","author":"Zeidan","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/pros.23281","article-title":"Myelodysplastic syndromes and acute myeloid leukemia after radiotherapy for prostate cancer: a population-based study","volume":"77","author":"Wang","year":"2017","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Canc"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3324\/haematol.2011.056283","article-title":"Acute myeloid leukemia developing in patients with autoimmune diseases","volume":"97","author":"Ramadan","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004836-198009000-00003","article-title":"Acute myelogenous leukemia in patients with ulcerative colitis","volume":"2","author":"Fabry","year":"1980","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00277-017-2954-5","article-title":"Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome","volume":"96","author":"Weed","year":"2017","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.blre.2017.07.003","article-title":"The skin as a window to the blood: cutaneous manifestations of myeloid malignancies","volume":"31","author":"Li","year":"2017","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1573397112666160815125148","article-title":"Rheumatologic manifestations of hematologic neoplasms","volume":"13","author":"Wang","year":"2017","journal-title":"Curr Rheumatol Rev"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib29","first-page":"721","article-title":"Rheumatic manifestations in myelodysplastic syndromes","volume":"18","author":"Castro","year":"1991","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.beha.2019.02.002_bib30","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1080\/1042819021000016186","article-title":"Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Saif","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.beha.2019.02.002_bib31","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib32","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.canep.2014.08.003","article-title":"Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the general practice research database","volume":"38","author":"Wilson","year":"2014","journal-title":"Canc Epidemiol"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib33","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1182\/blood.V95.10.3176","article-title":"Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer","volume":"95","author":"Ramenghi","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1385\/IR:31:1:47","article-title":"PI3K\/AKT signaling and systemic autoimmunity","volume":"31","author":"Patel","year":"2005","journal-title":"Immunol Res"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1383-5742(01)00057-6","article-title":"Mutations in apoptosis genes: a pathogenetic factor for human disease","volume":"488","author":"Mullauer","year":"2001","journal-title":"Mutat Res"},{"issue":"19","key":"10.1016\/j.beha.2019.02.002_bib36","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2174\/092986707781368423","article-title":"Targeting the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside","volume":"14","author":"Martelli","year":"2007","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1365-2141.2001.03114.x","article-title":"Risk of haematological malignancies in HLA-B27 carriers","volume":"115","author":"Au","year":"2001","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1399-0039.1979.tb00828.x","article-title":"HLA-B17 and the HLA-A1, B17 haplotype in acute myelogenous leukemia","volume":"14","author":"Heise","year":"1979","journal-title":"Tissue Antigens"},{"issue":"3\u20134","key":"10.1016\/j.beha.2019.02.002_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428199409059592","article-title":"Human major histocompatibility complex contains several leukemia susceptibility genes","volume":"12","author":"Dorak","year":"1994","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrd1342","article-title":"Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention","volume":"3","author":"Braddock","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.beha.2019.02.002_bib41","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.V97.7.2121","article-title":"Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination","volume":"97","author":"Stucki","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib42","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/sj.leu.2403457","article-title":"Interleukin-1 beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways","volume":"18","author":"Turzanski","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/338261","article-title":"Influence of interleukin-1 receptor antagonist gene polymorphism on disease","volume":"34","author":"Witkin","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib44","first-page":"239","article-title":"Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies","volume":"2","author":"Demeter","year":"1996","journal-title":"Cytokines Mol Ther"},{"issue":"6917","key":"10.1016\/j.beha.2019.02.002_bib45","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.beha.2019.02.002_bib46","article-title":"NF-kappaB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib47","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.18632\/oncotarget.3545","article-title":"Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib48","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1128\/MCB.19.8.5785","article-title":"NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1","volume":"19","author":"Guttridge","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib49","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1357-2725(97)00088-5","article-title":"Achieving transcriptional specificity with NF-kappa B","volume":"29","author":"Perkins","year":"1997","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib50","first-page":"725","article-title":"Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma","volume":"23","author":"Xie","year":"2010","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI200421358","article-title":"NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression","volume":"114","author":"Huber","year":"2004","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-kappaB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.beha.2019.02.002_bib53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-kappaB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Canc"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1189\/jlb.0113006","article-title":"Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia","volume":"94","author":"Zhou","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib55","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2567.2006.02430.x","article-title":"Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity","volume":"119","author":"Kim","year":"2006","journal-title":"Immunology"},{"issue":"15","key":"10.1016\/j.beha.2019.02.002_bib56","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081660","article-title":"Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment","volume":"18","author":"Gbolahan","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beha.2019.02.002_bib58","article-title":"Tumor evasion from T cell surveillance","volume":"2011","author":"Topfer","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"13","key":"10.1016\/j.beha.2019.02.002_bib59","article-title":"Immune evasion in acute myeloid leukemia: current concepts and future directions","volume":"1","author":"Teague","year":"2013","journal-title":"J Immunother Canc"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ejh.13182","article-title":"Molecular pathogenesis of acquired aplastic anemia","volume":"102","author":"Boddu","year":"2019","journal-title":"Eur J Haematol"},{"issue":"7540","key":"10.1016\/j.beha.2019.02.002_bib62","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib63","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/17474086.2018.1503049","article-title":"Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place","volume":"11","author":"Shallis","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"14","key":"10.1016\/j.beha.2019.02.002_bib64","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"issue":"1\u20133","key":"10.1016\/j.beha.2019.02.002_bib65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0167-4781(98)00139-0","article-title":"Secondary leukemias induced by topoisomerase-targeted drugs","volume":"1400","author":"Felix","year":"1998","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib66","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.V99.6.1909","article-title":"Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia","volume":"99","author":"Pedersen-Bjergaard","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2019.02.002_bib67","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaoncol.2016.6435","article-title":"Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia","volume":"3","author":"Ertz-Archambault","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0165-4608(97)00456-1","article-title":"Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7\/7q","volume":"104","author":"Kwong","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib69","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1476-5381.2010.01100.x","article-title":"Therapy-related myeloid neoplasms: pathobiology and clinical characteristics","volume":"162","author":"Sill","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib70","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.11034","article-title":"Therapy-related leukemia and myelodysplasia: susceptibility and incidence","volume":"92","author":"Leone","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.21014","article-title":"Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency","volume":"83","author":"Yenson","year":"2008","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib72","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/WNL.0b013e318211c3c8","article-title":"Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes","volume":"76","author":"Hasan","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib73","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/art.22641","article-title":"Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data","volume":"56","author":"Chakravarty","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","article-title":"Understanding the epidemiology and progression of systemic lupus erythematosus","volume":"39","author":"Pons-Estel","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib75","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002281-199909000-00005","article-title":"The role of sex hormones in systemic lupus erythematosus","volume":"11","author":"Lahita","year":"1999","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib76","first-page":"208","article-title":"Treatment of systemic lupus erythematosus - 2013 update","volume":"71","author":"Belmont","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.beha.2019.02.002_bib78","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3899\/jrheum.080214","article-title":"Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus","volume":"35","author":"Urowitz","year":"2008","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib79","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/acr.22173","article-title":"Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies","volume":"66","author":"Yurkovich","year":"2014","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.beha.2019.02.002_bib80","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","article-title":"Cancer risk in systemic lupus: an updated international multi-centre cohort study","volume":"42","author":"Bernatsky","year":"2013","journal-title":"J Autoimmun"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib81","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib82","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/art.1780390625","article-title":"Malignancy in systemic lupus erythematosus","volume":"39","author":"Abu-Shakra","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib83","first-page":"217","article-title":"Increased risk of malignancy in patients with systemic lupus erythematosus","volume":"46","author":"Ramsey-Goldman","year":"1998","journal-title":"J Invest Med"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/03009740252937568","article-title":"Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus","volume":"31","author":"Bjornadal","year":"2002","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib85","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.1780400424","article-title":"Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus","volume":"40","author":"Mellemkjaer","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib86","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.leukres.2014.06.025","article-title":"Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies","volume":"38","author":"Apor","year":"2014","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib87","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.61.5.409","article-title":"Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades","volume":"61","author":"Moss","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beha.2019.02.002_bib88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1422.008","article-title":"Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center","volume":"1108","author":"Tarr","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib89","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.rdc.2005.01.002","article-title":"Exploring the links between systemic lupus erythematosus and cancer","volume":"31","author":"Bernatsky","year":"2005","journal-title":"Rheum Dis Clin N Am"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib90","first-page":"74","article-title":"Clinical experiences with the L.E. cell test","volume":"22","author":"Lee","year":"1955","journal-title":"J Mt Sinai Hosp N Y"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib91","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archinte.1967.00300030087017","article-title":"Systemic lupus erythematosus and acute myeloblastic leukemia. Report of their coexistence and a survey of possible associating features","volume":"120","author":"Deaton","year":"1967","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib92","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.0954-6820.1980.tb09727.x","article-title":"Azathioprine and subacute myelomonocytic leukemia","volume":"207","author":"Vismans","year":"1980","journal-title":"Acta Med Scand"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib93","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/ard.40.4.422","article-title":"A case of systemic lupus erythematosus with sideroblastic anaemia terminating in erythroleukaemia","volume":"40","author":"Ng","year":"1981","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib94","first-page":"1965","article-title":"[Acute promyelocytic leukemia developed in the course of systemic lupus erythematosus: a case report]","volume":"31","author":"Taguchi","year":"1990","journal-title":"Rinsho Ketsueki"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02990942","article-title":"Acute megakaryoblastic leukaemia in a patient with systemic lupus erythematosus","volume":"14","author":"Colovic","year":"1997","journal-title":"Med Oncol"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib96","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/rheumatology\/kep204","article-title":"Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers","volume":"48","author":"Lofstrom","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib97","first-page":"1625","article-title":"Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents","volume":"19","author":"Vasquez","year":"1992","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib98","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1182\/blood.V89.12.4659","article-title":"Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation","volume":"89","author":"Meloni","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib99","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/03009740701483063","article-title":"Erythroleukaemia complicating ANA-negative systemic lupus erythematosus","volume":"36","author":"Eilertsen","year":"2007","journal-title":"Scand J Rheumatol"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2010.08.006","article-title":"Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan","volume":"123","author":"Chen","year":"2010","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib101","first-page":"887","article-title":"Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California","volume":"19","author":"Parikh-Patel","year":"2008","journal-title":"Canc Causes Control"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib102","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib103","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3899\/jrheum.101133","article-title":"Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study","volume":"38","author":"Myasoedova","year":"2011","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib104","first-page":"62","article-title":"Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis","volume":"29","author":"Turesson","year":"2002","journal-title":"J Rheumatol"},{"issue":"9688","key":"10.1016\/j.beha.2019.02.002_bib105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0140-6736(09)61432-X","article-title":"Rheumatoid arthritis: strategy more important than agent","volume":"374","author":"Sokka","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib106","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/ard.2009.123976","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40744-016-0032-4","article-title":"Emerging therapies for rheumatoid arthritis","volume":"3","author":"Kalden","year":"2016","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.beha.2019.02.002_bib108","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib109","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40744-017-0064-4","article-title":"Malignancy incidence, management, and prevention in patients with rheumatoid arthritis","volume":"4","author":"Wilton","year":"2017","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib111","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.30134","article-title":"The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan","volume":"63","author":"Chen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib112","first-page":"958","article-title":"National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study","volume":"30","author":"Thomas","year":"2003","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib113","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.semarthrit.2007.08.006","article-title":"Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population","volume":"37","author":"Abasolo","year":"2008","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib114","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials","volume":"127","author":"Michaud","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.beha.2019.02.002_bib115","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.beha.2019.02.002_bib116","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib117","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib118","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish biologics register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib119","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib120","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib121","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00296-004-0502-9","article-title":"Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy","volume":"25","author":"Choi","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.beha.2019.02.002_bib122","first-page":"423","article-title":"Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil","volume":"52","author":"Balakrishnan","year":"2004","journal-title":"J Assoc Phys India"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib123","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/SMJ.0b013e318188950a","article-title":"Adalimumab-induced acute myelogenic leukemia","volume":"101","author":"Saba","year":"2008","journal-title":"South Med J"},{"issue":"11","key":"10.1016\/j.beha.2019.02.002_bib124","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isomaki","year":"1978","journal-title":"J Chron Dis"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib125","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Canc"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(87)90490-6","article-title":"Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study","volume":"83","author":"Baker","year":"1987","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib128","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib129","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/rheumatology\/35.8.738","article-title":"Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study","volume":"35","author":"Jones","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib130","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.1780400906","article-title":"Rheumatoid arthritis and the risk of malignancy","volume":"40","author":"Cibere","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib131","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib132","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/ken130","article-title":"Cancer risk in hospitalized rheumatoid arthritis patients","volume":"47","author":"Hemminki","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl A","key":"10.1016\/j.beha.2019.02.002_bib133","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working party of the 2005 Montreal world congress of gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.beha.2019.02.002_bib134","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ibd.20545","article-title":"What is the peak age for onset of IBD?","volume":"14","author":"Johnston","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MPG.0000000000001455","article-title":"Extraintestinal manifestations of pediatric inflammatory bowel disease: prevalence, presentation, and anti-TNF treatment","volume":"65","author":"Greuter","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.beha.2019.02.002_bib136","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/DDDT.S11290","article-title":"Current and emerging drugs for the treatment of inflammatory bowel disease","volume":"5","author":"Triantafillidis","year":"2011","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib137","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ibd.20776","article-title":"How should we treat severe acute steroid-refractory ulcerative colitis?","volume":"15","author":"Cohen","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib138","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib139","first-page":"1025","article-title":"Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn's disease and review of the literature","volume":"31","author":"Mir Madjlessi","year":"1986","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib140","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J","article-title":"Extraintestinal cancers in inflammatory bowel disease","volume":"56","author":"Greenstein","year":"1985","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.beha.2019.02.002_bib141","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib142","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/ajg.2016.239","article-title":"Higher risk for hematological malignancies in inflammatory bowel disease: a nationwide population-based study in taiwan","volume":"111","author":"Wang","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.beha.2019.02.002_bib143","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1080\/10428190701345433","article-title":"Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy","volume":"48","author":"Zeidan","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib144","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.mayocp.2015.03.024","article-title":"Effect of medications on risk of cancer in patients with inflammatory bowel diseases: a population-based cohort study from olmsted county, Minnesota","volume":"90","author":"Yadav","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.beha.2019.02.002_bib145","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib146","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00054725-199905000-00005","article-title":"Concurrent inflammatory bowel disease and myelodysplastic syndromes","volume":"5","author":"Harewood","year":"1999","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib147","doi-asserted-by":"crossref","first-page":"661","DOI":"10.7326\/0003-4819-117-8-661","article-title":"The association between the myelodysplastic syndromes and Crohn disease","volume":"117","author":"Eng","year":"1992","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib148","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0889-8588(18)30329-0","article-title":"Immunologic abnormalities in myelodysplastic syndromes","volume":"6","author":"Hamblin","year":"1992","journal-title":"Hematol Oncol Clin N Am"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib149","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002689900401","article-title":"Cytokines in inflammatory bowel disease","volume":"22","author":"Rogler","year":"1998","journal-title":"World J Surg"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib150","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1590-8658(01)80046-3","article-title":"Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study","volume":"33","author":"Viscido","year":"2001","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.beha.2019.02.002_bib151","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/1097-0142(19861001)58:7<1569::AID-CNCR2820580731>3.0.CO;2-U","article-title":"Colorectal and extracolonic malignancy in ulcerative colitis","volume":"58","author":"Mir-Madjlessi","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2019.02.002_bib152","doi-asserted-by":"crossref","first-page":"95","DOI":"10.21037\/sci.2017.11.04","article-title":"Stem cell transplant in inflammatory bowel disease: a promising modality of treatment for a complicated disease course","volume":"4","author":"Salem","year":"2017","journal-title":"Stem Cell Invest"},{"issue":"4 Multiple Sclerosis","key":"10.1016\/j.beha.2019.02.002_bib153","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/01.CON.0000433290.15468.21","article-title":"Diagnosis and differential diagnosis of multiple sclerosis","volume":"19","author":"Katz Sand","year":"2013","journal-title":"Continuum (Minneap Minn)"},{"issue":"17","key":"10.1016\/j.beha.2019.02.002_bib154","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"9350","key":"10.1016\/j.beha.2019.02.002_bib155","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.beha.2019.02.002_bib156","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/01.wnl.0000324422.69067.e7","article-title":"Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone","volume":"71","author":"Bosca","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib157","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cancergencyto.2008.01.004","article-title":"Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis","volume":"182","author":"Ramkumar","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"issue":"18","key":"10.1016\/j.beha.2019.02.002_bib158","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","volume":"74","author":"Marriott","year":"2010","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.beha.2019.02.002_bib159","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.0b013e31828cf891","article-title":"Mitoxantrone-related acute leukemia in MS: an open or closed book?","volume":"80","author":"Chan","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1191\/1352458502ms836oa","article-title":"A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis","volume":"8","author":"Ghalie","year":"2002","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.beha.2019.02.002_bib161","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1177\/1352458509107015","article-title":"Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required","volume":"15","author":"Pascual","year":"2009","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib162","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3324\/haematol.2010.036657","article-title":"Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis","volume":"96","author":"Ammatuna","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib163","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1352458508100967","article-title":"Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?","volume":"15","author":"Ellis","year":"2009","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib164","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.WNL.0000095425.84407.39","article-title":"The use of mitoxantrone (novantrone) for the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology","volume":"61","author":"Goodin","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib165","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib166","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00296-006-0167-7","article-title":"Scleroderma and chronic myeloid leukemia: a sheer coincidence, a consequence of long lasting D-penicillamine therapy or a plausible relationship of both diseases?","volume":"27","author":"Kasifoglu","year":"2006","journal-title":"Rheumatol Int"},{"issue":"9","key":"10.1016\/j.beha.2019.02.002_bib167","first-page":"895","article-title":"[Concordant improvement of progressive systemic sclerosis and chronic myelogenous leukemia with interferon-alpha treatment]","volume":"35","author":"Watanabe","year":"1994","journal-title":"Rinsho Ketsueki"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib168","first-page":"425","article-title":"[Scleroderma, Gougerot-Sjogren syndrome and myelomonocytic leukemia]","volume":"56","author":"Dupond","year":"1989","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"10.1016\/j.beha.2019.02.002_bib169","article-title":"Haematological malignancies in systemic sclerosis patients: case reports and review of the world literature","volume":"2017","author":"Colaci","year":"2017","journal-title":"Case Rep Rheumatol"},{"issue":"11","key":"10.1016\/j.beha.2019.02.002_bib170","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood.V104.11.4714.4714","article-title":"Association between vasculitides and myelodysplastic syndrome (MDS): a report on 21 cases","volume":"104","author":"Fain","year":"2004","journal-title":"Blood"},{"issue":"9992","key":"10.1016\/j.beha.2019.02.002_bib171","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(15)61165-5","article-title":"Leukaemic vasculitis with myelodysplastic syndrome","volume":"386","author":"Odell","year":"2015","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.beha.2019.02.002_bib172","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1200\/JCO.2011.34.6965","article-title":"Large-vessel vasculitis as an early manifestation of chronic myelomonocytic leukemia","volume":"29","author":"Park","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib173","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/bmt.2009.228","article-title":"Successful allogeneic bone marrow transplantation for chronic myelomonocytic leukemia complicated by refractory aortitis","volume":"45","author":"Mori","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib174","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13256-017-1239-x","article-title":"Migratory large vessel vasculitis preceding acute myeloid leukemia: a case report","volume":"11","author":"Chandratilleke","year":"2017","journal-title":"J Med Case Rep"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib175","first-page":"846","article-title":"Acute myeloid leukemia associated with necrotizing temporal arteritis","volume":"30","author":"Warrington","year":"2003","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib176","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<200::AID-AJH6>3.0.CO;2-0","article-title":"Myelodysplastic syndromes with nephrotic syndrome","volume":"60","author":"Saitoh","year":"1999","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib177","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2362.2004.01417.x","article-title":"Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts","volume":"34","author":"Voulgarelis","year":"2004","journal-title":"Eur J Clin Investig"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib178","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jnci\/50.3.633","article-title":"Immune complex disease in the kidneys of lymphoma-leukemia patients: the presence of an oncornavirus-related antigen","volume":"50","author":"Sutherland","year":"1973","journal-title":"J Natl Cancer Inst"},{"issue":"5\u20136","key":"10.1016\/j.beha.2019.02.002_bib179","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10428199509059648","article-title":"Glomerular injury in chronic myelomonocytic leukemia","volume":"18","author":"Morschhauser","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2019.02.002_bib180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrneph.2010.171","article-title":"Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis","volume":"7","author":"Lien","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib181","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.ackd.2013.07.004","article-title":"Kidney involvement in leukemia and lymphoma","volume":"21","author":"Luciano","year":"2014","journal-title":"Adv Chron Kidney Dis"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib182","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0272-6386(99)70047-8","article-title":"Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders","volume":"34","author":"Au","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib183","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1681\/ASN.2007050532","article-title":"A new look at platelet-derived growth factor in renal disease","volume":"19","author":"Floege","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.beha.2019.02.002_bib184","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5414\/CNP67176","article-title":"Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy","volume":"67","author":"Dwyer","year":"2007","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1016\/j.beha.2019.02.002_bib185","first-page":"738","article-title":"Membranoproliferative glomerulonephritis secondary to chronic myeloid leukemia","volume":"21","author":"Subramanian","year":"2010","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"8697","key":"10.1016\/j.beha.2019.02.002_bib186","first-page":"1078","article-title":"Criteria for diagnosis of behcet's disease. International study group for behcet's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib187","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.24423","article-title":"Epidemiology and clinical characteristics of Behcet's disease in the US: a population-based study","volume":"61","author":"Calamia","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib188","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF02982607","article-title":"Successful cord blood stem cell transplantation for myelodysplastic syndrome with Behcet disease","volume":"77","author":"Yamato","year":"2003","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.beha.2019.02.002_bib189","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00277-003-0819-6","article-title":"Resolution of Behcet's disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syndrome","volume":"83","author":"Tomonari","year":"2004","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib190","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s002770050255","article-title":"Behcet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behcet's symptoms","volume":"74","author":"Budak-Alpdogan","year":"1997","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib191","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/1096-8652(200101)66:1<57::AID-AJH1010>3.0.CO;2-3","article-title":"Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature","volume":"66","author":"Vaiopoulos","year":"2001","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2019.02.002_bib192","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2169\/internalmedicine.56.7808","article-title":"Successful treatment of behcet's disease associated with acute myeloid leukemia with myelodysplasia-related changes using azacitidine and tacrolimus before allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Nakamura","year":"2017","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib193","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/rheumatology\/ken413","article-title":"Resolution of Behcet's disease after non-myeloablative allogeneic stem cell transplant for acute myeloid leukaemia","volume":"48","author":"Lim","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.beha.2019.02.002_bib194","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/rheumatology\/ken162","article-title":"Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8","volume":"47","author":"Ahn","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"5 Suppl 42","key":"10.1016\/j.beha.2019.02.002_bib195","first-page":"S115","article-title":"The association of Behcet's disease with myelodysplastic syndrome in Japan: a review of the literature","volume":"24","author":"Tada","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.beha.2019.02.002_bib196","doi-asserted-by":"crossref","first-page":"e0190182","DOI":"10.1371\/journal.pone.0190182","article-title":"Cancer risk in Korean patients with Behcet's disease: a nationwide population-based study","volume":"12","author":"Jung","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib197","first-page":"56","article-title":"[Development of acute myelocytic leukemia in the course of Sjogren's syndrome]","volume":"30","author":"Wakita","year":"1989","journal-title":"Rinsho Ketsueki"},{"issue":"7","key":"10.1016\/j.beha.2019.02.002_bib198","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1346-8138.1998.tb02435.x","article-title":"Primary Sjogren's syndrome followed by chronic myelogenous leukemia: a case report with a ten year history","volume":"25","author":"Minowa","year":"1998","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2019.02.002_bib199","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02284066","article-title":"Chronic myelomonocytic leukemia and primary Sjogren's syndrome","volume":"7","author":"Ponge","year":"1988","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.beha.2019.02.002_bib200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clim.2017.07.021","article-title":"Rheumatic paraneoplastic syndromes - a clinical link between malignancy and autoimmunity","volume":"186","author":"Manger","year":"2018","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib201","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00296-005-0005-3","article-title":"Paraneoplastic rheumatic syndromes","volume":"26","author":"Andras","year":"2006","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.beha.2019.02.002_bib202","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.2004.051771","article-title":"Risk of haematopoietic cancer in patients with inflammatory bowel disease","volume":"54","author":"Askling","year":"2005","journal-title":"Gut"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618301154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618301154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:10Z","timestamp":1761498310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618301154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":202,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1521692618301154"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid disorders after autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}